PMID- 26554232
OWN - NLM
STAT- MEDLINE
DCOM- 20151216
LR  - 20191113
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 61
IP  - 9
DP  - 2015
TI  - Homocysteine in Chronic Heart Failure.
PG  - 1137-45
AB  - BACKGROUND: Hyperhomocysteinemia (HHcy) is a risk factor for cardiovascular 
      disease. Homocysteine (Hcy) can generate reactive oxygen species. Oxidative 
      stress enhances the progression of cardiovascular diseases and has long been 
      implicated in chronic heart failure (CHF). This study was to evaluate the 
      predictive value of plasma Hcy levels in CHF patients and to investigate the 
      relationship with other markers. METHODS: We investigated 134 adult CHF patients 
      (males, 74%; mean age, 60.0 +/- 14.8 years). Echocardiography, 6-min walk test, and 
      determination of peak oxygen consumption (VO(2max)) were performed. Serum levels 
      of Hcy and other markers were determined. Clinical follow-up was performed at 
      five years. RESULTS: The mean Hcy level was markedly elevated in CHF patients 
      (18.4 +/- 7.83 mumol/L) vs. control subjects (12.8 +/- 3.14 mumol/L; p < 0.01), 
      whatever the etiology of heart failure (non-ischemic, n = 74, 17.6 +/- 7.8 mumol/L; 
      ischemic, n = 60, 19.3 +/- 7.8 mumol/L). Hcy correlated negatively with VO(2max) and 
      positively with BNP. Kaplan-Meier analysis showed that CHF patients with HHcy > 
      15 mumol/L had a significantly lower survival rate (35% vs. 56%, log-rank p < 
      0.05) than those without HHcy. Cox regression revealed that HHcy and hs-CRP were 
      the most powerful independent predictors of mortality in patients at 5 years. 
      CONCLUSIONS: HHcy is common in CHF patients and is associated with an increased 
      risk of death at 5 years. We suggest that Hcy can be used in clinical practice as 
      an additional risk marker in CHF patients with various medications.
FAU - Fournier, Pauline
AU  - Fournier P
FAU - Fourcade, Joelle
AU  - Fourcade J
FAU - Roncalli, Jerome
AU  - Roncalli J
FAU - Salvayre, Robert
AU  - Salvayre R
FAU - Galinier, Michel
AU  - Galinier M
FAU - Causse, Elizabeth
AU  - Causse E
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Biomarkers)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers
MH  - Comorbidity
MH  - Female
MH  - Follow-Up Studies
MH  - France/epidemiology
MH  - Heart Failure/*blood/drug therapy/etiology/mortality
MH  - Homocysteine/*blood
MH  - Humans
MH  - Hyperhomocysteinemia/*blood/epidemiology
MH  - Kaplan-Meier Estimate
MH  - Kidney Diseases/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Oxidative Stress
MH  - Oxygen Consumption
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Young Adult
EDAT- 2015/11/12 06:00
MHDA- 2015/12/19 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
AID - 10.7754/clin.lab.2015.141238 [doi]
PST - ppublish
SO  - Clin Lab. 2015;61(9):1137-45. doi: 10.7754/clin.lab.2015.141238.